Page 6 - Joan Shen News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Joan shen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Joan Shen Today - Breaking & Trending Today
亚美旗舰厅 newsonlinee.cc - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsonlinee.cc Daily Mail and Mail on Sunday newspapers.
I-Mab Biopharma (IMAB) Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Share this article Share this article SHANGHAI and GAITHERSBURG, Md., Feb. 10, 2021 /PRNewswire/ I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for TJ210/MOR210 to initiate a phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ210/MOR210 monotherapy in patients with advanced solid tumors. TJ210/MOR210 is a monoclonal antibody developed by MorphoSys that is directed against complement factor C5a receptor 1 (C5aR1). Produced in the tumoral microenvironment, its ligand C5a acts as a chemoattractant to recruit tumor-promoting cells such as myeloid-derived suppressor cells, M2 macrophages and neutrophils. TJ210/MOR210 is ....
Press release content from PR Newswire. The AP news staff was not involved in its creation. I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S. February 5, 2021 GMT I-MAB Logo (PRNewsfoto/I-Mab Biopharma) SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced multiple clinical advancements for its proprietary and highly differentiated CD73 antibody, uliledlimab (also known as TJD5, or TJ004309) in advanced solid tumors. The Company plans to present detailed clinical results at select scientific conferences this year. ....
Share this article Share this article SHANGHAI and GAITHERSBURG, Md., Feb. 4, 2021 /PRNewswire/ I-Mab (the Company ) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in a phase 2 clinical trial (NCT04600817) of TJ107 (efineptakin alpha), a novel long-acting recombinant human interleukin-7 (rhIL-7), in patients with glioblastoma multiforme (GBM) in China. The phase 2 trial is a randomized, single-blind, placebo-controlled study to evaluate the efficacy and safety of TJ107 in lymphopenic patients with newly diagnosed GBM who have been treated with standard concurrent chemoradiotherapy. The study s goal is to determine the proportion of patients with an increase in the absolute lymphocyte counts and associated clinical response after the administration of the first TJ107 dose. ....